Repairogen Corp.

Repairogen Corp. specializes in advanced regenerative medicine solutions aimed at promoting tissue repair. The company focuses on innovative therapies designed to enhance patient care across various medical applications. Repairogen Corp.

was founded in 2012 in Ithaca, US, as a biotechnology firm focusing on regenerative medicine. The company has completed 2 deals, with its most recent funding round being a Seed round in September 2017, raising USD 1. 000 mn led by Kairos Ventures. The total amount raised by the company stands at USD 1.

000 mn. Repairogen specializes in innovative solutions for the biotechnology sector. The core offerings include advanced regenerative medicine therapies that utilize proprietary techniques for tissue repair and regeneration, applicable in orthopedic repair, wound healing, and organ restoration. The company serves hospitals, rehabilitation centers, and specialty clinics primarily in North America, Europe, and select regions in Asia, with a strong focus on improving patient outcomes through ongoing research and development.

Repairogen’s revenue model is based on B2B partnerships and direct sales to healthcare providers. The company sells its regenerative therapies to hospitals and clinics through a subscription model or one-time purchases, with pricing tailored to client needs based on volume and usage frequency. This structure supports consistent revenue generation while fostering long-term client relationships. Repairogen plans to leverage the recent Seed funding of USD 1.

000 mn raised in September 2017 to support the development of new regenerative therapies. The company is also looking to expand into new markets in Asia and Europe by 2025. Their strategy includes the launch of additional products aimed at addressing specific healthcare challenges, enhancing their offerings within the regenerative medicine sector.